Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 6, 2024
Patient and nursing staff perspectives on automated scalp cooling (ASC) for chemotherapy-induced alopecia in breast cancerBenjamin E Ueberroth, Heidi E Kosiorek, Nellie N Nafissi, et al.
Springerplus|February 4, 2015
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatmentAnne Blaes, Daniel Duprez, Todd Defor, et al.
Oncology Reports|February 3, 2018
Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cellsSeiga Ohmine, Jeffrey L Salisbury, James Ingle, et al.
JMIR Medical Informatics|March 26, 2021
Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot StudyTufia Haddad, Jane M Helgeson, Katharine E Pomerleau, et al.
Journal of Proteome Research|December 15, 2010
Hexapeptide libraries for enhanced protein PTM identification and relative abundance profiling in whole human salivaSricharan Bandhakavi, Susan K Van Riper, Pierre N Tawfik, et al.
Plos One|May 13, 2014
Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cellsMateusz Opyrchal, Jeffrey L Salisbury, Shuya Zhang, et al.
Oncotarget|December 7, 2017
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cellsMateusz Opyrchal, Malgorzata Gil, Jeffrey L Salisbury, et al.
Frontiers in Oncology|June 14, 2024
Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancerAndrew Takchi, Minzhi Zhang, Mohammad Jalalirad, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Collaborative large language models (LLMs) are all you need for screening in systematic reviewsMihir Parmar, Syed Arsalan Ahmed Naqvi, Kainat Warraich, et al.
Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.
Pageof 3